Crippa L, Klein D, Linder A
J Genet Hum. 1976 Mar;24(1):1-13.
The authors studied a group of 16 patients suffering from rheumatic diseases, who were being treated with Butazolidine (Phenylbutazone). The control cases were divided into two groups: one consisted of six patients who were suffering from the same chronic rheumatic diseases, but who were being treated with other drugs; the other group consisted of 15 normal persons whose age and sex corresponded, more or less, with those of the group of patients treated with Butazolidine. A chromosomal examination of the lymphocytes of the peripheral blood was carried out on the 16 patients and the 21 persons not being treated with Butazolidine. A comparison of the karyotypes of all the individuals studied showed no significant difference in the number of breakages between the three groups. Statistical analysis confirmed that the differences in the percentages of chromosomal damage were not significant.
作者研究了一组16名患有风湿性疾病且正在使用保泰松（苯基丁氮酮）治疗的患者。对照病例分为两组：一组由6名患有相同慢性风湿性疾病但正在使用其他药物治疗的患者组成；另一组由15名年龄和性别与使用保泰松治疗的患者组大致相符的正常人组成。对16名患者和21名未使用保泰松治疗的人的外周血淋巴细胞进行了染色体检查。对所有研究个体的核型进行比较，结果显示三组之间的断裂数没有显著差异。统计分析证实，染色体损伤百分比的差异不显著。
